Track 4: Cancer Prevention Product Research and Review for Postdoctoral Research Fellows

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

This fellowship will provide training in cancer prevention (e.g., chemoprevention, vaccination, and early detection). Individuals will be trained in the drug, biologic, or device development and approval processes and their application to study populations (including healthy subjects) to facilitate the movement of novel approaches from the bench to the community. Combining training in public health, cancer prevention research, and research-related regulatory overview will allow individuals to develop expertise across these disciplines.

Training Goals and Outcomes

  • Understanding the design and analysis of clinical trials, familiarity with the IRB approval process, and determining appropriate clinical endpoints in cancer prevention and early detection trials.
  • Participation in multidisciplinary cancer prevention research
  • Understanding the review process for regulatory pathways
  • Understanding and participation in the development of product standards and guidance documents, particularly with respect to regulations for use of agents with limited preclinical data in humans
  • Understanding of critical ethical issues and requirements in product research, development, and review, including protection of human research subjects and conflict of interest
  • Understanding and developing guidelines for use of agents in chemoprevention trials that have approved indications only in the treatment setting
  • Understanding and developing criteria for "acceptable drug toxicity" in chemoprevention trials, where study subjects are often healthy volunteers
  • Understanding and developing criteria to determine acceptable surrogate clinical endpoints unique to cancer prevention trials (in contrast to treatment endpoints: e.g., tumor response, survival)

Eligibility Requirements

  • Doctoral degree (M.D., Ph.D., or equivalent)
  • U.S. citizenship or permanent residency at the time of application (September 1)
  • Applicants must have less than 5 years relevant postdoctoral training at the time of appointment

Curricula and Responsibilities

First Year

Individuals will pursue a master's degree in clinical investigation (M.S.) or in public health (M.P.H). Those already possessing a master's degree, will come directly to the NCI/FDA and begin the activities described below.

Second Through Fourth Year

At the NCI fellows will participate in the NCI's Summer Curriculum in Cancer Prevention, Molecular Prevention Laboratory, weekly Fellows Research Meetings and Colloquia series, Grants and Grantsmanship Workshop, Effective Presentations Workshop, and other professional development activities.

At the FDA, depending upon research interests, fellows will choose from among the product or clinical divisions of the participating FDA Centers. In a particular product division, fellows interested in regulatory research and related regulatory experience will work with a principal investigator or branch chief (or designee) selected through mutual agreement. Fellows may elect to work in a product division or in a pharmacology/toxicology branch in a clinical division. Both clinical and non-clinical fellows will have the option of performing translational research in the participating division, branch, or office.

Fellows will participate in various regulatory activities of the division at the FDA where they undertake their research. Fellows will spend approximately 40% of their time in product, pharmacology/toxicology, or clinical reviews and policy and guidance document development. They will participate in grand rounds and meetings related to regulatory activities. Additionally, fellows will attend courses offered by the participating FDA Centers and pass required testing in reviewer training.

Fellows' performance will be evaluated by Fellowship Program staff at the NCI and FDA, research mentors, and scientific staff overseeing fellows' activities at either institution.

How to Apply

Applications are due August 25, 2018 for an earliest start date of July 1, 2019.

Please submit:

  • Curriculum Vitae
  • Personal statement of research goals
  • Three letters of reference

For more detailed information and application guidelines view the NCI-FDA Research and Regulatory Review Fellowships
Guidelines for Application (PDF)

Where To Submit:

Mentors

While at FDA, fellows will each be assigned a mentor who will be a senior member of FDA scientific review staff.

Review list of mentors and projects here.

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source and a link to this page included, e.g., “Track 4: Cancer Prevention Product Research and Review for Postdoctoral Research Fellows was originally published by the National Cancer Institute.”

Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artists, or publisher to obtain permission for reuse.

We welcome your comments on this post. All comments must follow our comment policy.